Century Therapeutics (NASDAQ:IPSC) Earns “Buy” Rating from EF Hutton Acquisition Co. I

EF Hutton Acquisition Co. I reiterated their buy rating on shares of Century Therapeutics (NASDAQ:IPSCGet Rating) in a report issued on Thursday morning, Benzinga reports. EF Hutton Acquisition Co. I currently has a $16.00 target price on the stock.

IPSC has been the topic of a number of other reports. SVB Leerink decreased their price objective on Century Therapeutics from $20.00 to $14.00 and set an outperform rating on the stock in a research report on Friday, January 6th. HC Wainwright reiterated a buy rating and issued a $19.00 price objective on shares of Century Therapeutics in a research report on Thursday, February 9th. Piper Sandler decreased their price objective on Century Therapeutics from $24.00 to $14.00 and set an overweight rating on the stock in a research report on Friday, January 6th. Finally, Chardan Capital started coverage on Century Therapeutics in a research report on Tuesday, December 27th. They issued a buy rating and a $19.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus target price of $19.00.

Century Therapeutics Price Performance

IPSC stock opened at $3.86 on Thursday. The business has a fifty day moving average price of $4.53 and a 200 day moving average price of $7.68. Century Therapeutics has a fifty-two week low of $3.54 and a fifty-two week high of $14.02. The company has a quick ratio of 13.44, a current ratio of 13.44 and a debt-to-equity ratio of 0.02.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. UBS Group AG bought a new position in Century Therapeutics during the fourth quarter worth about $28,000. Barclays PLC lifted its holdings in Century Therapeutics by 533.3% during the fourth quarter. Barclays PLC now owns 5,408 shares of the company’s stock worth $28,000 after acquiring an additional 4,554 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in Century Therapeutics during the fourth quarter worth about $41,000. Tower Research Capital LLC TRC lifted its holdings in Century Therapeutics by 27.8% during the third quarter. Tower Research Capital LLC TRC now owns 4,157 shares of the company’s stock worth $41,000 after acquiring an additional 904 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in Century Therapeutics during the fourth quarter worth about $53,000. 35.81% of the stock is currently owned by institutional investors.

About Century Therapeutics

(Get Rating)

Century Therapeutics, Inc, a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.

See Also

Analyst Recommendations for Century Therapeutics (NASDAQ:IPSC)

Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.